FAST: Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Poulsen, Lars K
Jensen, Bettina M
Kowalski, Marek L
Mills, Clare En
Papadopoulos, Nikos G
Schnoor, Heidi J
van den Hout, Rob
Versteeg, Serge A
van Ree, Ronald
MetadataShow full item record
CitationClin Transl Allergy 2012, 2(1):5
AbstractABSTRACT: The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication.
DescriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to Clinical and translational allergy
- Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.
- Authors: Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, Quaak S, Akkerdaas JH, Blom L, Asturias J, Bindslev-Jensen C, Bernardi ML, Clausen M, Ferrara R, Hauer M, Heyse J, Kopp S, Kowalski ML, Lewandowska-Polak A, Linhart B, Maderegger B, Maillere B, Mari A, Martinez A, Mills EN, Neubauer A, Nicoletti C, Papadopoulos NG, Portoles A, Ranta-Panula V, Santos-Magadan S, Schnoor HJ, Sigurdardottir ST, Stahl-Skov P, Stavroulakis G, Stegfellner G, Vázquez-Cortés S, Witten M, Stolz F, Poulsen LK, Fernandez-Rivas M, Valenta R, van Ree R
- Issue date: 2015
- Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract.
- Authors: Fernández-Rivas M, Garrido Fernández S, Nadal JA, Díaz de Durana MD, García BE, González-Mancebo E, Martín S, Barber D, Rico P, Tabar AI
- Issue date: 2009 Jun
- Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy.
- Authors: Freidl R, Gstoettner A, Baranyi U, Swoboda I, Stolz F, Focke-Tejkl M, Wekerle T, van Ree R, Valenta R, Linhart B
- Issue date: 2017 Jun
- Hypoallergenic molecules for subcutaneous immunotherapy.
- Authors: Jongejan L, van Ree R, Poulsen LK
- Issue date: 2016
- Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
- Authors: Rondón C, Blanca-López N, Campo P, Mayorga C, Jurado-Escobar R, Torres MJ, Canto G, Blanca M
- Issue date: 2018 Apr